Summary: comparative evidence for tovorafenib versus other systemic options

No randomized comparison of tovorafenib with any other therapy has been reported as of September 2026. The phase 3 LOGGIC/FIREFLY-2 trial, which compares tovorafenib with investigator's choice of standard chemotherapy in first-line RAF-altered pLGG, completed enrollment of approximately 400 participants in May 2026, with preliminary results expected in 2027. The only formal indirect comparison identified is the EU Joint Clinical Assessment (JCA) of tovorafenib in relapsed or refractory pLGG, endorsed on 30 April 2026. Of 8 PICO questions, the developer submitted comparative data for 2 (PICO 5 and PICO 7), and the assessors included 1: an unanchored matching-adjusted indirect comparison (MAIC) of FIREFLY-1 against a phase I/II dabrafenib plus trametinib study in the BRAF V600E subpopulation. The effective sample size was 5.81 to 14.26. For independent review committee (IRC)-assessed progression-free survival (PFS) by RANO-LGG, the hazard ratio was 4.88 (95% CI 2.14 to 11.14; nominal p = 0.011), a direction unfavorable to tovorafenib; objective response comparisons were inconclusive; and the odds ratio for grade 3 or higher adverse events was 12.65 (95% CI 2.30 to 69.58). The assessors stated that these estimates "should not necessarily be interpreted as causal effects of treatment." The comparison with trametinib (TRAM-01) was excluded because the comparator was reported only in conference abstracts.

Independent reviews published in 2025 and 2026 compare agents on mechanism and indication rather than head-to-head efficacy. Type I BRAF inhibitors (dabrafenib, vemurafenib) are restricted to BRAF V600-mutant tumors because of paradoxical MAPK activation in BRAF fusion-driven tumors, whereas tovorafenib is active in both fusion and V600 tumors. Reviewers describe once-weekly dosing without food restrictions and an available oral suspension for tovorafenib, compared with once- or twice-daily dosing for MEK and BRAF inhibitors. Reviewers also describe differences in adverse event profiles: reduced growth velocity has been reported only with tovorafenib, and intratumoral hemorrhage was reported in 9% of the pooled pediatric tovorafenib safety population, while pyrexia is more frequent with dabrafenib plus trametinib and cardiac and ocular monitoring is emphasized for MEK inhibitors. A 2026 systematic review found rebound regrowth after MAPK inhibitor discontinuation in at least 23 of 131 evaluable participants (17.6%) and 1 rebound event among 24 evaluable FIREFLY-1 participants who entered a drug holiday, while noting short post-discontinuation follow-up.

Direct randomized comparisons: status of LOGGIC/FIREFLY-2

“The primary analysis is expected to occur approximately 12 months after the last patient is enrolled; preliminary insights are expected to be available in 2027.” (opens the source at this quote in a new tab)
“It is being conducted at approximately 140 sites across the U.S., Canada, Europe, Australia, South America, Middle East and Asia, and in just over three years has enrolled approximately 400 participants who are receiving either tovorafenib once weekly or one of four standard of care (SoC) chemotherapy regimens.” (opens the source at this quote in a new tab)

EU joint clinical assessment: comparators and data submitted per PICO

Population and PICO	Comparator	Results submitted	Data included in the JCA report
Population 1 (full claimed indication), PICO 3	“Combination of carboplatin and vincristine”	“no”	“no”
Population 1 (full claimed indication), PICO 4	“Vinblastine”	“no”	“no”
Population 2 (BRAF V600E mutation in patients > 1 year), PICO 5	“Combination of dabrafenib and trametinib”	“yes”	“yes”
Population 3 (BRAF fusion, rearrangement, or V600 [non-E] mutation), PICO 7	“Trametinib”	“yes”	“no”

“The HTD does not include comparative evidence addressing patients in the full claimed indication, corresponding to PICOs 1-4 in the assessment scope.” (opens the source at this quote in a new tab)
“For PICO 5, all included relative effectiveness and safety results are based on unanchored MAIC methods. The results presented for these outcomes are associated with a number of major uncertainties and the effect estimates should not necessarily be interpreted as causal” (opens the source at this quote in a new tab)

Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, efficacy

Outcome	Tovorafenib (FIREFLY-1)	Dabrafenib plus trametinib (Bouffet 2023)	ESS	Relative effect
6-month PFS, RANO-LGG, IRC	“94 [85, 100]”	“86 [75, 98]”	“5.81”	“RR: 1.09 [0.92; 1.30]”
12-month PFS, RANO-LGG, IRC	“76 [52, 100]”	“83 [71, 96]”	“5.81”	“RR: 0.92 [0.61, 1.38]”
CR+PR by RANO-HGG, investigator	“40.0 [12.2, 73.8]”	“52.8 [NR, NR]”	“6.64”	“OR: 0.56 [0.08, 3.84]”
CR+PR by RANO-HGG, IRC	“50.0 [18.7, 81.3]”	“19.4 [8.2, 36.0]”	“6.64”	“OR: 7.26 [0.98, 53.68]”
PFS by RANO-LGG, IRC, median months	“13.67 [4.60, 24.87]”	“36.9 [36.0, NE]”	“5.81”	“4.88 [2.14, 11.14]”

“Hazard ratios less than 1 indicate longer PFS with tovorafenib” (opens the source at this quote in a new tab)
“Values reported in these cells correspond to the unadjusted FIREFLY-1 data, i.e., prior to MAIC-weighting. The corresponding weighted values were not reported by the HTD.” (opens the source at this quote in a new tab)

Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, safety

Outcome	Tovorafenib (FIREFLY-1)	Dabrafenib plus trametinib (Bouffet 2023)	ESS	Odds ratio [95% CI]
Severe AE (CTCAE grade 3 or higher)	“20 (22)”	“22 (36)”	“14.26”	“12.65 [2.30, 69.58]”
Serious AE	“13 (22)”	“15 (36)”	“14.26”	“3.04 [0.77, 12.10]”
Treatment interruption due to AE	“15 (22)”	“26 (36)”	“14.26”	“1.15 [0.28, 4.76]”
Treatment discontinuation due to AE	“3 (22)”	“8 (36)”	“14.26”	“0.58 [0.11, 3.03]”
Death related to AE	“2 (22)”	“0 (36)”	Not reported	“NA: Indirect comparison not provided due to zero event rate in dabrafenib + trametinib group”

EU joint clinical assessment: uncertainties of the indirect comparison

“The Bouffet 2023 study included small proportions of patients with a diagnosis of high-grade glioma (HGG) (rather than paediatric LGG) or who had not received prior systemic therapy.” (opens the source at this quote in a new tab)
“All treatment effect estimates are associated with a risk of bias of unknown magnitude and direction due to residual confounding. This is likely to arise from identified prognostic variables and/or effect modifiers (PVs/EMs) that were not adjusted for in the MAIC, including histological type, primary tumour location and prior chemotherapy” (opens the source at this quote in a new tab)
“The effective sample size (ESS) for the analyses of all outcomes is small (ranging from 5.81 to 14.26), leading to statistical imprecision (i.e., wide confidence intervals) for the resulting effect estimates.” (opens the source at this quote in a new tab)
“The analysis of IRC-assessed ORR by RANO-LGG, presented by the HTD, is not included due to the use of methodologically flawed and inappropriate analysis methods.” (opens the source at this quote in a new tab)
“There is a substantial difference between INV- and IRC-assessed ORR by RANO-HGG in Bouffet 2023. The reason for this difference is unclear.” (opens the source at this quote in a new tab)

EU joint clinical assessment: comparison with trametinib not assessed

“The HTD provides an unanchored MAIC of tovorafenib with trametinib for PICO 7. However, this comparison based on the studies FIREFLY-1 and TRAM-01 is not included in the JCA report due to insufficient information available for the assessment of TRAM-01.” (opens the source at this quote in a new tab)

“Its comparator was trametinib, and the only evidence available for that arm came from a trial (TRAM-01) reported solely in conference abstracts rather than in a full publication.” (opens the source at this quote in a new tab)

Independent commentary on the joint clinical assessment findings

“Overall survival could not be estimated at all. The only outcome reaching nominal statistical significance was progression-free survival, and it favored the comparator. Objective response was inconclusive.” (opens the source at this quote in a new tab)
“On the descriptive safety data, tovorafenib showed numerically more serious and severe adverse events than the comparator.” (opens the source at this quote in a new tab)
“Yet the limitations are so pervasive – small numbers, an unanchored comparison – that the report cannot conclude the drug is inferior.” (opens the source at this quote in a new tab)

Mechanism-based selection: type II RAF inhibitor versus type I BRAF inhibitors

“BRAF targeted therapy should be selected in a mutation-specific fashion. Type 1 BRAFi (i.e., dabrafenib) are not effective against BRAF fusions and can result in paradoxical activation and tumor progression. Tovorafenib is effective in recurrent pLGG with BRAFV600 or BRAF fusions, while dabrafenib is ineffective in tumors with BRAF fusions.” (opens the source at this quote in a new tab)

“Type I RAF inhibitors such as dabrafenib are not indicated for the treatment of tumors harboring a BRAF fusion due to paradoxical activation which may increase the risk of tumor growth (10). Prior to the approval of tovorafenib, there were no approved targeted therapies for patients with pLGG harboring BRAF fusions.” (opens the source at this quote in a new tab)

Review table: regulatory status and key considerations by agent

Molecular target	Drug	Regulatory status	Key considerations
BRAF V600E	Dabrafenib plus trametinib	“Approved (FDA/EMA/Canada)”	“First-line pLGG; superior to chemotherapy (ORR 47% vs 11%);AEs: Pyrexia (68%), headache, rash, weight gain; optimal duration unknown”
BRAF fusion	Trametinib	“Not pLGG-specific (FDA/EMA/Canada)”	“Second-line option when treatment required; avoids paradoxical MAPK activation; not yet approved as a first lineAEs: Acneiform rash, GI symptoms, elevated CPK; rebound risk on discontinuation”
BRAF fusion or V600E	Tovorafenib	“FDA: Accelerated approval (April 2024); EMA/Canada: Under review”	“Active in fusion and V600E tumors; CNS-penetrant; ORR 51%AEs: Rash (93%), hair color changes, fatigue, hemorrhage, reduced growth velocity; frontline trials ongoing”
NF1-associated pLGG	Selumetinib	“FDA/EMA/Canada: Approved for NF1 PN only (off-label for pLGG)”	“Could be used off-label for NF1-associated pLGG but access remains difficult off study.AEs: GI symptoms, elevated CPK, acneiform rash, paronychia; cardiac and ocular monitoring required”

Review table: evidence in pLGG by agent

Drug	Target	Evidence in pLGG
Dabrafenib	“B-raf enzyme”	“Phase II evidence:- 47% ORR when combined with dabrafenib in BRAFv600E-mutant pLGG (26)”
Selumetinib	“MEK1/2”	“Phase I evidence:- 20% sustained PR (20)Phase II evidence:-36% sustained PR (19)”
Trametinib	“MEK1/2”	“Phase II evidence:- 47% ORR when combined with dabrafenib in BRAF v600E-mutant pLGG (26)- Retrospective evidence for monotherapy (34–36)”
Tovorafenib	“RAF kinase”	“Phase II evidence:- 67% ORR by RANO-HGG and 51% ORR by RAPNO criteria (37)”

Adverse event profiles across MAPK inhibitor classes

“The common acute adverse effects of the type II RAF inhibitor tovorafenib included hair color change (Figure 2E), anemia, elevated creatine kinase, and cutaneous reactions. Importantly, a reversible decrease in growth velocity (Figure 2F), and an increased incidence of intra-tumoral hemorrhage were reported. Pyrexia, diarrhea, and weight gain were reported to be less common than MEK/BRAF inhibitors, and no signs of ocular and cardiac toxicity were reported.” (opens the source at this quote in a new tab)

“While most toxicities of MAPKi therapies are thought to be a direct effect of MAPKi inhibition, type I BRAFi are selective mutant inhibitors, which can proceed to paradoxical activation of the MAPK pathway resulting in secondary skin malignancy;27,28 this is not seen with type II RAFi and MEKi.” (opens the source at this quote in a new tab)
“Similarly, reductions in growth velocity have only been observed in patients with pLGG treated with tovorafenib.” (opens the source at this quote in a new tab)

“Interestingly, tovorafenib can lead to growth arrest – a side effect that hasn’t been reported with any of the MEK inhibitors, and it is unknown whether this particular toxicity is considered a class effect.” (opens the source at this quote in a new tab)

Intracranial hemorrhage across MAPK inhibitors

“In the phase 2 FIREFLY-1 trial of tovorafenib in BRAF-altered pLGG (n = 137), any-site hemorrhage of any grade occurred in 42% of patients with grade 3-4 hemorrhage in 7 patients (5%) and, separately, one fatal grade 5 intratumoral hemorrhage; in the overlapping pooled FDA-label safety population (N = 140), intratumoral hemorrhage specifically was reported in 9%.” (opens the source at this quote in a new tab)
“Reported incidence varies by agent, population, and hemorrhage ascertainment method (active imaging-based surveillance versus clinical reporting), from < 1% symptomatic ICH with dabrafenib in adult melanoma to 9% intratumoral hemorrhage in the pooled pediatric tovorafenib safety population.” (opens the source at this quote in a new tab)

“The presence of a KIAA1549::BRAF fusion in the tumor had the strongest association with hemorrhage, persisting across multivariable models (approximately sixfold increased risk), although estimates were limited by low event number. MAPK inhibitor exposure (specifically binimetinib and tovorafenib) was associated with hemorrhage in univariate analysis but partially confounded by fusion status.” (opens the source at this quote in a new tab)

Dosing schedule, formulation, and route compared with other agents

“The availability of a liquid formulation, a weekly dosing regimen (in contrast to daily doses for other available BRAF/MEK inhibitors) and lack of food effect, may make drug compliance easier for young patients.” (opens the source at this quote in a new tab)

“Based on pharmacokinetic studies, MEK and BRAF inhibitors are given daily (once to twice per day), with some MEK inhibitors requiring an empty stomach for optimal absorbtion (45, 55). Tovorafenib can be taken with or without food and is administered once weekly.” (opens the source at this quote in a new tab)

Rebound regrowth after discontinuation: pan-RAF inhibitor versus earlier agents

“it seems that the incidence of RR following pan-RAF inhibitors may be lower compared to earlier generation drugs, although these findings should be interpreted with caution given the relatively short post-discontinuation follow-up (range: 0.6–10.9 months), limiting detection of delayed events (30).” (opens the source at this quote in a new tab)

Targeted therapy versus chemotherapy in BRAF V600-mutant pLGG: meta-analysis

“Ten studies (16 treatment arms; 4 RCTs, 6 RS were included). Pooled ORR was 42.35% (95% CI, 29.41-55.29), and the median PFS was 23.03 months (95% CI, 17.18-28.88). Grade 3/4 AEs occurred in 30.56% (95% CI, 22.60-38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy.” (opens the source at this quote in a new tab)
“Emerging evidence suggests potential benefit in selected molecularly defined patients; however, further prospective studies are required to define their role in first-line treatment.” (opens the source at this quote in a new tab)

Cost-effectiveness of first-line dabrafenib plus trametinib versus chemotherapy

“Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY” (opens the source at this quote in a new tab)

Weight gain with dabrafenib plus trametinib in first-line pediatric low-grade glioma

“However, weight gain as an adverse event or an increase of at least 2 BMI-for-age percentiles was reported in 32 of 73 patients who received dabrafenib plus trametinib.” (opens the source at this quote in a new tab)
“Our analysis suggests that tumor location does not appear to be associated with the weight gain observed with dabrafenib plus trametinib, findings that support other reports that suggest weight gain as a safety signal with MAPK-targeted therapy in this patient population.” (opens the source at this quote in a new tab)

Any-grade adverse events and reasons for dose modification with dabrafenib plus trametinib compared with carboplatin and vincristine

“Overall, 106 patients were included in the safety analysis (73 for dabrafenib plus trametinib and 33 for chemotherapy).” (opens the source at this quote in a new tab)
“The most common adverse events of any grade with dabrafenib plus trametinib as compared with chemotherapy were pyrexia (in 68% vs. 18%), headache (in 47% vs. 27%), and vomiting (in 34% vs. 48%).” (opens the source at this quote in a new tab)
“Among the patients who received dabrafenib plus trametinib, dose adjustments or interruptions were more frequent because of pyrexia (in 53% vs. 0 with chemotherapy) and were less frequent because of a decreased neutrophil count (in 3% vs. 27% with chemotherapy).” (opens the source at this quote in a new tab)
“Although skin toxic effects (including dry skin and rash) occurred more frequently with dabrafenib plus trametinib, only 8% of patients had resultant dose interruption or adjustment.” (opens the source at this quote in a new tab)

Progression events by independent versus investigator assessment in the comparator trial

“A discrepancy in progression events was noted between independent and investigator assessments in the two trial groups (30 vs. 9 events with dabrafenib plus trametinib and 22 vs. 9 with chemotherapy).” (opens the source at this quote in a new tab)
“Strict interpretation of the RANO criteria by the independent reviewer may have contributed to the higher number of progression events reported as compared with investigator review, because the criteria for progressive disease are sensitive to increases relative to nadir, regardless of changes from baseline.” (opens the source at this quote in a new tab)

Hemorrhage rates by individual MAPK pathway inhibitor

“Binimetinib showed a particularly strong association (3/17 patients, 17.6%; HR 6.24, 95% CI 1.55–25.11, p = 0.010, OR 5.00)” (opens the source at this quote in a new tab)
“Selumetinib (0/11), trametinib (1/9, 11.1%), and dabrafenib (0/6) showed no significant associations.” (opens the source at this quote in a new tab)
“Cytotoxic chemotherapy, radiation, and other systemic therapies (including anti-angiogenic agents) were not associated with increased hemorrhage risk.” (opens the source at this quote in a new tab)

EU joint clinical assessment: failed attempt to construct external control arms for the comparisons without trial data

“For the PICOs with a lack of published data on the comparator (PICOs 1 to 4, 6 and 8), the HTD described an attempt to construct external control arms using patient data acquired outside of clinical studies to allow comparative effectiveness analyses. The HTD performed a feasibility study to identify suitable data sources to construct the external control arms. According to the HTD, one US database initially demonstrated feasibility for use but was deemed unsuitable due to an insufficient number of patients with BRAF alterations and adequate follow-up in the R/R setting. The HTD concluded that finding a fit-for-purpose and reliable comparator data source was not possible.” (opens the source at this quote in a new tab)
“The HTD's approach to include studies with an individualised treatment comparator, only if the comparator included all treatment options, is not adequate.” (opens the source at this quote in a new tab)

Germany: orphan drug rule restricting the benefit assessment to patient numbers and costs

“In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier. After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit.” (opens the source at this quote in a new tab)

Tovorafenib (DAY101)

Product comparison